TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.27
-0.48% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.9M
Taysha Gene Therapies Inc (TSHA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+5.5%
Last 4 quarters
Revenue YoY growth
+171.3%
Most recent quarter
EPS YoY growth
-4.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.2%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+9.8%
2025-08-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-04 | $-0.07 | +23.4% | $4.53 | $4.49 | -0.9% |
| 2025-11-13 | $-0.09 | -9.4% | $4.36 | $4.13 | -5.3% |
| 2025-08-12 | $-0.08 | -14.3% | $2.76 | $3.03 | +9.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.10 | $-0.07 | +23.4% | $5.49M | +171.3% |
| 2025-09-30 | $-0.08 | $-0.09 | -9.4% | — | — |
| 2025-06-30 | $-0.07 | $-0.08 | -14.3% | $1.99M | +78.6% |
| 2025-03-31 | $-0.09 | $-0.07 | +22.2% | $2.30M | -32.5% |
| 2024-12-31 | $-0.08 | $-0.07 | +12.5% | $2.02M | -43.9% |
| 2024-09-30 | $-0.09 | $-0.07 | +22.2% | $1.79M | -62.3% |
| 2024-06-30 | $-0.16 | $-0.09 | +43.8% | $1.11M | -53.6% |
| 2024-03-31 | $-0.11 | $-0.10 | +9.1% | $3.41M | — |
| 2023-12-31 | $-0.11 | $0.92 | +936.4% | $3.60M | — |
| 2023-09-30 | $-0.17 | $-0.13 | +23.5% | $4.75M | — |
| 2023-06-30 | $-0.31 | $-0.38 | -22.6% | $2.40M | — |
Frequently asked questions
Has Taysha Gene Therapies Inc beaten earnings estimates?
Taysha Gene Therapies Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +5.5% over the last 4 quarters.
How does TSHA stock react to earnings?
TSHA stock has moved an average of +1.2% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Taysha Gene Therapies Inc's revenue growth rate?
Taysha Gene Therapies Inc reported year-over-year revenue growth of +171.3% in its most recent quarter, with EPS growing -4.6% year-over-year.